Sign up
Pharma Capital

Cancer Diagnostics group VolitionRX looks ahead to 2018

Cameron Reynolds CEO of Volition RX (NYSE:VNRX) talks to Proactive about the company's low cost, easy to use blood test (requiring just a single drop) - called Nu.Q test. Detail here too on new patents granted this year, strengthening Volition's intellectual portfolio as well as how their new cost-effective research laboratory in Belgium will increase their profitability as well as their ability to launch even more products worldwide. Cameron says Volition's scientific team has tripled in the last two years allowing an increase in trials capacity massively, which means the company is spot-on target for 2018.


View full VNRX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.